End-of-day quote
Shanghai S.E.
03:30:00 09/05/2024 am IST
|
5-day change
|
1st Jan Change
|
8.26
CNY
|
+2.99%
|
|
+4.82%
|
-13.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,586
|
6,929
|
9,595
|
6,085
|
4,207
|
3,608
|
-
|
Enterprise Value (EV)
1 |
3,586
|
6,929
|
9,595
|
6,085
|
4,207
|
3,608
|
3,608
|
P/E ratio
|
20.8
x
|
34.1
x
|
32.9
x
|
19.4
x
|
18
x
|
10.1
x
|
8.26
x
|
Yield
|
-
|
-
|
0.92%
|
1.6%
|
1.68%
|
-
|
-
|
Capitalization / Revenue
|
1.97
x
|
-
|
3.1
x
|
1.95
x
|
1.72
x
|
1.13
x
|
0.96
x
|
EV / Revenue
|
1.97
x
|
-
|
3.1
x
|
1.95
x
|
1.72
x
|
1.13
x
|
0.96
x
|
EV / EBITDA
|
-
|
-
|
16.3
x
|
11.6
x
|
9.36
x
|
7.13
x
|
5.85
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
4.62
x
|
2.73
x
|
1.75
x
|
1.3
x
|
1.13
x
|
Nbr of stocks (in thousands)
|
4,41,609
|
4,41,609
|
4,41,569
|
4,41,569
|
4,41,002
|
4,36,791
|
-
|
Reference price
2 |
8.120
|
15.69
|
21.73
|
13.78
|
9.540
|
8.260
|
8.260
|
Announcement Date
|
30/03/20
|
29/03/21
|
29/03/22
|
18/04/23
|
19/04/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,817
|
-
|
3,097
|
3,119
|
2,453
|
3,179
|
3,757
|
EBITDA
1 |
-
|
-
|
587.7
|
524.9
|
449.6
|
506
|
617
|
EBIT
1 |
-
|
-
|
478
|
399.5
|
301
|
463
|
573
|
Operating Margin
|
-
|
-
|
15.43%
|
12.81%
|
12.27%
|
14.56%
|
15.25%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
483.7
|
399.4
|
300.5
|
499
|
611
|
Net income
1 |
-
|
202.8
|
291.4
|
311.7
|
230.9
|
360
|
441
|
Net margin
|
-
|
-
|
9.41%
|
9.99%
|
9.41%
|
11.32%
|
11.74%
|
EPS
2 |
0.3900
|
0.4600
|
0.6600
|
0.7100
|
0.5300
|
0.8200
|
1.000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.2000
|
0.2200
|
0.1600
|
-
|
-
|
Announcement Date
|
30/03/20
|
29/03/21
|
29/03/22
|
18/04/23
|
19/04/24
|
-
|
-
|
Fiscal Period: December |
2023 Q1
|
---|
Net sales
1 |
686.9
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
85.12
|
Net margin
|
12.39%
|
EPS
2 |
0.1900
|
Dividend per Share
|
-
|
Announcement Date
|
18/04/23
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
12.2%
|
15.2%
|
14.1%
|
10.3%
|
12.9%
|
13.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
6.32%
|
7.53%
|
-
|
7.2%
|
8%
|
Assets
1 |
-
|
-
|
4,608
|
4,137
|
-
|
5,000
|
5,512
|
Book Value Per Share
2 |
-
|
-
|
4.700
|
5.050
|
5.450
|
6.330
|
7.330
|
Cash Flow per Share
2 |
-
|
-
|
0.9300
|
1.050
|
1.000
|
-0.3100
|
1.930
|
Capex
1 |
-
|
-
|
653
|
296
|
227
|
100
|
100
|
Capex / Sales
|
-
|
-
|
21.08%
|
9.48%
|
9.24%
|
3.15%
|
2.66%
|
Announcement Date
|
30/03/20
|
29/03/21
|
29/03/22
|
18/04/23
|
19/04/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -13.42% | 485M | | +9.48% | 27.38B | | -30.22% | 3.08B | | -15.44% | 2.51B | | +18.49% | 2.45B | | +7.04% | 2.09B | | -4.11% | 2.05B | | +1.67% | 1.55B | | +0.59% | 1.29B | | +23.78% | 1.23B |
Medical Supplies
|